Meagan Parrish
Lead Editor | LinkedInMeagan Parrish is the lead editor for PharmaVoice. She got her professional start as an editor at a women’s magazine in her current home of Madison, Wisconsin, before jumping into B2B industry reporting. She spent three years covering the chemicals, energy, food and healthcare sectors at numerous publications, and then became a full-time pharma journalist. During her four years as senior editor at Pharma Manufacturing, Meagan was a three-time Neal Awards finalist, and was honored to receive numerous other accolades for her industry reporting. Her highest honor was the Stephen Barr Award, a prestigious “best in show” award chosen from the 2020 pool of Gold-winning articles by the American Society of Business Publication Editors (ASBPE) for her coverage of contaminated APIs in drugs imported from overseas. Pharma Manufacturing also snagged the 2021 Magazine of the Year award from ASBPE. Meagan joined PharmaVoice in late 2021 after the publication was acquired by Industry Dive and relaunched as a daily digital. But Meagan’s most important job is being Mom to her two daughters and teaching them to cook, dance and talk in funny accents.
140 articles by Meagan Parrish
-
Where are they now? 4 biotechs that soared then crashed during the pandemic
Nov. 15, 2024 -
Spravato is just the beginning in a new wave of depression meds
Nov. 11, 2024 -
2024 PharmaVoice 100s: Rare Disease Warriors
Oct. 29, 2024 -
J&J’s comeback kid Spravato heads for blockbuster status
Oct. 25, 2024 -
2024 PharmaVoice 100s: Patient Champions
Oct. 22, 2024 -
Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with
Oct. 18, 2024 -
2024 PharmaVoice 100s: Trailblazers
Oct. 16, 2024 -
2024 PharmaVoice 100s: Standout Leaders
Oct. 14, 2024 -
BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s
Oct. 11, 2024 -
An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?
Oct. 4, 2024 -
Fresh data intensifies race for a major gene therapy target
Sept. 25, 2024 -
After epilepsy setback, Ovid charges confidently ahead in CNS
Sept. 20, 2024 -
Who’s winning in biotech’s tight market?
Sept. 13, 2024 -
What 3 layoff stories reveal about pharma’s troubles
Sept. 6, 2024 -
Is anyone taking the world’s priciest drugs?
Aug. 30, 2024 -
What pharma has learned from AI
Aug. 2, 2024 -
In biotech’s new market normal, here’s what’s catching this investor’s eye
July 25, 2024 -
Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline
July 17, 2024 -
Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders
July 15, 2024 -
Up-and-comers look for an edge in the bustling ADC field
June 28, 2024 -
Pfizer’s Paxlovid flunks long COVID study as researchers uncover the condition’s deep toll
June 14, 2024 -
Pharma’s R&D gamble: picking pipeline winners in a risky field
June 7, 2024 -
Where competition is heating up in pharma
May 24, 2024 -
Why H5N1 has scientists and regulators on edge
May 17, 2024 -
The Enhertu effect: Daiichi’s plan to build on the success of its crown jewel
May 10, 2024